Long‐term intermittent oral administration of selective COX ‐2 inhibitor improved the clinical outcomes of COVID ‐19 in patients with cirrhosis
Journal of Digestive Diseases · 2024
DOI: 10.1111/1751-2980.13313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Digestive Diseases, 2024. Verfasst von Ming Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Cyclooxygenase 2 Inhibitors, COVID-19. Die Arbeit nennt 25 Literaturangaben. Gefördert von: National Natural Science Foundation of China, 135 Projects for Disciplines of Excellence of West China Hospital, Sichuan University.
Abstract (Originalsprache)
Objectives
Patients with cirrhosis are more susceptible to coronavirus disease 2019 (COVID‐19) due to immune dysfunction. In this retrospective study we aimed to investigate whether suppression of mild systemic inflammation with selective cyclooxygenase‐2 inhibitor (COX‐2‐I) during chronic care of cirrhotic patients would reduce the occurrence of acute decompensated events and improve patient prognosis of COVID‐19.
Methods
Medical records of cirrhotic patients with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection were sequentially reviewed. The patients were divided into the COX‐2‐I and control groups depending on whether they took oral selective COX‐2‐I for over 3 months or not. The primary outcomes included the occurrence of severe/critical COVID‐19, acute decompensated events, and acute‐on‐chronic liver failure (ACLF).
Results
After propensity score matching analysis, there were 314 cases in the control group and 118 cases in the COX‐2‐I group. Compared with the control group, the risk of severe/critical COVID‐19 in the COX‐2‐I group was significantly decreased by 83.1% ( p = 0.004). Acute decompensated events and ACLF occurred in 23 (7.32%) and nine (2.87%) cases in the control group, but none in the COX‐2‐I group ( p = 0.003 and 0.122). The rate of hospitalization in the COX‐2‐I group was significantly lower than that of the control group (3.39% vs 13.06%, p = 0.003). No patient in the COX‐2‐I group required intensive care unit admission.
Conclusions
Long‐term intermittent oral administration of selective COX‐2‐I in cirrhotic patients significantly reduces the occurrence of severe/critical COVID‐19, acute decompensated events, and ACLF. It may also be used for systemic inflammation caused by other pathogens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
- Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
ORCID-Profile: Hao Wu, Zhi Yin Huang
Förderung
- National Natural Science Foundation of China
- 135 Projects for Disciplines of Excellence of West China Hospital, Sichuan University
Zitieren
APA
Chen, M., Yang, Z., Gong, H., Wu, H., Liu, L., Jiang, J. S., Gao, J. H., Tang, C. W., & Huang, Z. Y. (2024). Long‐term intermittent oral administration of selective COX ‐2 inhibitor improved the clinical outcomes of COVID ‐19 in patients with cirrhosis. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13313
Vancouver
Chen M, Yang Z, Gong H, Wu H, Liu L, Jiang JS, et al. Long‐term intermittent oral administration of selective COX ‐2 inhibitor improved the clinical outcomes of COVID ‐19 in patients with cirrhosis. Journal of Digestive Diseases. 2024. doi:10.1111/1751-2980.13313
BibTeX
@article{Chen2024,
author = {Chen, Ming and Yang, Zhu and Gong, Hui and Wu, Hao and Liu, Ling and Jiang, Jing Sun and Gao, Jin Hang and Tang, Cheng Wei and Huang, Zhi Yin},
title = {Long‐term intermittent oral administration of selective COX ‐2 inhibitor improved the clinical outcomes of COVID ‐19 in patients with cirrhosis},
journal = {Journal of Digestive Diseases},
year = {2024},
doi = {10.1111/1751-2980.13313}
}
EUVIMED